Antibody biodistribution coefficients: Inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human

Cited by (262)

Items 201–262 of 262

1. Measurement of specific and nonspecific tissue uptake of antibodies in tumor by SPECT imaging and nonlinear compartmental modeling
   Nicholas Cho, Jason Ho, Geoffrey Del Rosario, Shang‐Fan Yu, Gregory Z. Ferl, C. Andrew Boswell · 2025 · EJNMMI Research
2. PK/PD of Positively Charged ADC in Mice
   Hsuan‐Ping Chang, Huyen Khanh Le, Shufang Liu, Dhaval K. Shah · 2025 · Pharmaceutics
3. Effect of Acute Lung Injury (ALI) Induced by Lipopolysaccharide (LPS) on the Pulmonary Pharmacokinetics of an Antibody
   Shweta Jogi, Dhaval K. Shah · 2025 · Antibodies
4. Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice
   Aruni Jha, Melanie Doyle‐Eisele, David Revelli, Trevor J. Carnelley, Douglas Barker, Shantha Kodihalli · 2022 · Viruses
5. Prediction of tissue concentrations of monoclonal antibodies in mice from plasma concentrations
   Iftekhar Mahmood, Million A. Tegenge · 2018 · Regulatory Toxicology and Pharmacology
6. Treatment of Sindbis Virus-Infected Neurons with Antibody to E2 Alters Synthesis of Complete and nsP1-Expressing Defective Viral RNAs
   Jane X. Yeh, Yunfan Fan, Maggie L. Bartlett, Xiaoyan Zhang, Norah Sadowski, Debra Hauer, Winston Timp, Diane E. Griffin · 2022 · mBio
7. A Non-radiometric Approach to Determine Tissue Vascular Blood Volume in Biodistribution Studies
   Hossein Salimi-Moosavi, Marcus Soto · 2022 · The AAPS Journal
8. Systemically Administered Anti-uPAR Antibody Plasma and Lung ELF Pharmacokinetics Characterized by Minimal Lung PBPK Model
   Sharad Sharma, Antony Leonard, Kathryn N. Phoenix, Hsueh Yuan Chang, Jun Wang, Steven B. Hansel · 2023 · AAPS PharmSciTech
9. Pharmacokinetics/Pharmacodynamics and Disposition of Antibody–Drug Conjugates
   Siddharth Sukumaran, Kedan Lin · 2025 · AAPS advances in the pharmaceutical sciences series
10. Intracerebroventricular phospho-tau immunotherapy alleviates cortical phospho-tau burden and motor phenotype in a neuron-specific P301S tauopathy mouse
    Susanna Kemppainen, Marta Aramburu-Núñez, Henna Koivisto, Adrián Posado-Fernández, M.R. Felix-Garcia, Katriina Nurminen, Sara Häkli, Enric Abellí‐Deulofeu, M. Kaisto, Antía Custodia et al. · 2025 · Experimental Neurology
11. Minibinders targeting Staphylococcus aureus α-toxin exert protective effects in vivo
    Jun Weng, Yang Hu, Keke Wang, Yuhua Chen, Yi Lin Yang, Banbin Xing, Lixin Ma, Zigong Wei · 2025 · International Journal of Biological Macromolecules
12. 89Zr-mAb uptake interpretation requires the use of tissue to plasma ratios corrected for antibody catabolism
    Marc C. Huisman, Johanna E. E. Pouw, Sandeep S.V. Golla, Damien G. Huglo, Franck Morschhauser, Josée M. Zijlstra, Jessica E. Wijngaarden, Mirte Stavenga, Hylke J. Sebus, Maarten Slebe et al. · 2025 · EJNMMI Research
13. Clinical Pharmacology Insights for Small Molecule and Antibody‐Based Drug Products Approved for Multiple Immune‐Mediated Indications
    Yan Xu, Bharath Kumar Kandadi Muralidharan, Konstantine W. Skordos · 2025 · The Journal of Clinical Pharmacology
14. Pharmacokinetic and biodistribution analysis of monoclonal antibodies: a comprehensive study of antibody biodistribution and partitioning coefficients in mice
    Zachary Rabow, Iman Samiee, Priyanka Desai, Xingrong Liu, Majlinda Thomas, Leslie A. Khawli, Brian Carr · 2025 · mAbs
15. Design and Synthesis of MBP-Fc-Bifunctional Peptide Inhibitor to Improve In Vivo Half-Life and Efficacy
    Rucha Mahadik, Kelly Schwinghamer, Andrea L. Villela-Nava, Teruna J. Siahaan, Thomas J. Tolbert · 2025 · Molecular Pharmaceutics
16. Laboratory safety evaluations of izenivetmab, a caninized anti-nerve growth factor monoclonal antibody, for three-month alleviation of osteoarthritic pain in dogs
    Adam D. Werts, Kayla Saad, Bernard D. Hummel, Lisa M. Mangus, Eric M. Green, Martin Guillot, Cathy Sue Carlson, Agathe Bédard, Rogely Waite Boyce, Christopher S. Knauer et al. · 2026 · The Veterinary Journal
17. Characterization of atypical Ebola virus disease in ferrets
    Wenguang Cao, Shihua He, Helene Schulz, Jordan Wight, Michael Chan, Karla Emeterio, Guodong Liu, Jonathan Audet, Kevin Tierney, Kimberly Azaransky et al. · 2026 · PLoS Pathogens
18. Whole-Body Pharmacokinetics of Ionizable Lipid, mRNA, and the Expressed Antibody following Intravenous Administration of mRNA-Loaded Lipid Nanoparticles
    Shrusti Tiwari, Mokshada Kumar, Shengjia Wu, Rutuja Kulkarni, Dhaval K. Shah · 2026 · The AAPS Journal
19. Advances in targeting IL-1 family cytokines for the treatment of inflammatory diseases
    Cem Gabay, Charlotte Girard-Guyonvarc’h, Laurie Vaillant, Matthias Jarlborg · 2026 · Nature Reviews Rheumatology
20. Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates
    Siddharth Sukumaran, Kedan Lin · 2015 · AAPS advances in the pharmaceutical sciences series
21. Absorption, Distribution, Metabolism, and Excretion of Biopharmaceutical Drug Products
    Molly Graveno, Robert E. Stratford · 2018 · Springer eBooks
22. Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA
    Anhye Kim, Min-Seok Oh, Gwan‐Ho Lee, Seongeun Song, Mi-sun Byun, Donghoon Choi, Byung Yong Yu, Howard Lee · 2024 · Antibody Therapeutics
23. Holistic in silico developability assessment of novel classes of small proteins using publicly available sequence-based predictors
    Daniel A. M. Pais, Jan-Peter A. Mayer, Karin Felderer, Maria B. Batalha, Timo Eichner, Sofia T. Santos, Raman Kumar, Sandra Regina Augusta da Silva, Hitto Kaufmann · 2024 · Journal of Computer-Aided Molecular Design
24. Novel Technologies for Generation of Bispecific Constructs
    Laurence Fayadat‐Dilman · 2018 · Springer eBooks
25. Monoclonal Antibody-Directed Therapy
    Veysel Kayser, Amita Datta‐Mannan · 2022 · MDPI eBooks
26. Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins in Systemic Lupus Erythematosus – Belimumab
    Herbert Struemper · 2019 · Wiley eBooks
27. Bioanalytical Strategies Enabling Successful ADC Translation
    Xiaogang Han, Steven B. Hansel, Lindsay King · 2016
28. An Introduction to Systems Biology and Quantitative Systems Pharmacology
    B.C. Gomes · 2017 · Elsevier eBooks
29. Modeling Approaches to Characterize the Disposition of Monoclonal Antibodies
    Ludivine Fronton · 2014
30. Mechanism and Physiologically Based PK / PD Model in Assisting Translation from Preclinical to Clinical: Understanding PK / PD of Therapeutic Proteins at Site‐of‐Action
    Xi Chen, Weirong Wang · 2019
31. Distribution of Biotechnology-Derived Biologics Drug Products
    Robert E. Stratford · 2021 · Springer eBooks
32. Distribution of Biotechnology-Derived Biologics Drug Products
    Robert E. Stratford · 2022 · Springer eBooks
33. How opsonins drive bacterial uptake
    Elena Boero · 2023
34. Predictive modelling and simulation for taming the chance and luck in biologics drug discovery
    Armin Sepp · 2023 · Proceedings of the Estonian Academy of Sciences
35. Novel biopharmaceuticals: Pharmacokinetics, pharmacodynamics, and bioanalytics
    Sieto Bosgra, Manish Gupta · 2024 · Elsevier eBooks
36. Investigation of Antibody Pharmacokinetics in Male Reproductive System and Its Characterization Using a Translational PBPK Model
    Sree Ojili, Dhaval K. Shah · 2025 · Antibodies
37. Pharmacokinetics of Therapeutic Antibodies and Derivatives
    Emile P. Chen · 2025 · Wiley eBooks
38. Reaching the Site of Action
    Emile P. Chen · 2025 · Wiley eBooks
39. Role of Data in Development and Application of Quantitative Systems Pharmacology Models
    Jason R. Chan, Abhishek Gulati, Mary E. Spilker, Erica L. Bradshaw‐Pierce · 2025 · Handbook of experimental pharmacology
40. Additional file 1 of Optimal imaging time points considering accuracy and precision of Patlak linearization for 89Zr-immuno-PET: a simulation study
    Jessica E. Wijngaarden, Marc C. Huisman, Johanna E. E. Pouw, C. Willemien Menke‐van der Houven van Oordt, Yvonne W. S. Jauw, Ronald Boellaard · 2022 · Figshare
41. Monoclonal antibodies targeting the rabies virus glycoprotein promotes viral clearance and Fc-dependent neuroprotection in the infected brain
    Seonhee Kim, Anthony Coléon, Florence Larrous, Lauriane Kergoat, Saïd Mougari, Julien Lannoy, Marta Simone Fabrício Tiago, David Hardy, Étienne Kornobis, Felix Augusto Rey et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
42. The core herpes simplex-1 fusion complex drives cell-to-cell spreading of pathological Tau
    Stefanie-Elisabeth Heumüller, Mikhail E. Sushkin, Elisa Sánchez-Sendín, André Hossinger, Dominik Stappert, Nazlican Altinisik, Louisa Seiwert, Lydia Paulsen, Adalbert Krawczyk, Barbara G. Klupp et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
43. Timing matters: early administration of a high-affinity antibody targeting the tau repeat domain prevents aggregation in a mouse tauopathy model
    Lewis K. Penny, Mohammad Arastoo, Richard A. Lofthouse, Aya Abdallah, Peter I. Imoesi, Karima Schwab, Helen Shiells, Valeria Melis, Gernot Riedel, Charles R. Harrington et al. · 2026 · Alzheimer s Research & Therapy
44. GD2-Targeted Minibody–Drug Conjugates Match the Potency of IgG-Based ADCs in a Mouse Cancer Model
    Daniel V. Kalinovsky, M.M. Titov, Irina V. Kholodenko, А. В. Кибардин, E. V. Svirshchevskaya, Sergey Mikhailovich Deyev, Roman V. Kholodenko · 2026 · International Journal of Molecular Sciences
45. The Effect of FcRn Binding on Ocular Disposition of Monoclonal Antibodies
    Sanika Naware, Saurav Prasanna Kulkarni, Sahil Salvi, Dhvani Patel, Dhaval K. Shah · 2026 · Antibodies
46. Déterminants moléculaires de la pharmacocinétique des anticorps thérapeutiques
    Guillaume Brachet · 2017
47. Pharmacocinétique et relation concentration-effet des anti-TNFα dans les maladies inflammatoires chroniques de l’intestin
    Antoine Petitcollin · 2019
48. Pharmacocinétique et relation dose-concentration-effet du rituximab dans la polyartrite rhumatoïde et les vascularités associées aux anticorps anti-cytoplasme des neutrophiles
    Amina Bensalem · 2019 · theses.fr (ABES)
49. Nouveaux biomarqueurs en imagerie du myélome multiple
    Clément Bailly · 2019
50. Dosage d’anticorps médicaments utilisés en cancérologie par spectrométrie de masse : application à une étude clinique
    Aurélien Millet · 2023
51. The Effects of Radioimmunotherapy and Antibiotics on Biofilm‐Associated Implant Infections in a Preclinical Rat Model
    F. Ruben H. A. Nurmohamed, Kevin J. H. Allen, Mackenzie E. Malo, Connor Frank, Colleen Nesbitt, J. Fred. F Hooning van Duyvenbode, M.A.S. Buijs, Berend van der Wildt, Alex J. Poot, Marnix G. E. H. Lam et al. · 2026 · Journal of Orthopaedic Research®
52. The biodistribution and effect of post-exposure neutralising monoclonal antibody treatment in a mouse model of SARS-CoV-2 infection with viral spread to the brain
    Janine Schlaepfer, Simon De Neck, Rebekah Penrice-Randal, Parul Sharma, Adam Kirby, Lee M. Tatham, Eduardo Gallardo Toledo, Joanne Herriott, Edyta Kijak, Joanne Sharp et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
53. Differential expression of monoclonal antibody in rat brain following systemic and local administration of AAV
    Ekram Ahmed Chowdhury, Guy M. L. Meno‐Tetang, Shufang Liu, Shengjia Wu, Navya Desireddy, Anthony Jerez, Leeha Mahmood, Aneesh Rajwade, Sidhaarth Bulusu, Tanguy Jamier et al. · 2026 · Journal of Pharmacokinetics and Pharmacodynamics
54. Intranasal drug delivery to the brain for neurodegenerative diseases: Current efforts and challenges in delivery platforms and modeling
    Katherine Y. Bang, Ross L. Walenga, Steven G. Chopski, Markham C. Luke, Ksenia Blinova, Liang Zhao, Su Guo · 2026 · Advanced Drug Delivery Reviews
55. Pharmacokinetic modeling frameworks for complex antibody-drug conjugates analytes: clinical pharmacology considerations
    Devendra Kumar, Arti Verma, Neerja Trivedi · 2026 · Biochemical Pharmacology
56. Adjunctive Varespladib after antivenom administration for snakebite: A phase II randomized clinical trial
    Charles John Gerardo, Ashish Bhalla, Chitta R. Mohanty, Badal K. Sahu, Surendra Kumar, Suneil Agrawal, Sugunananthagopan Manu Ayyan, Eileen Shu, Travis Deuson, Madhu Kumar Ravikumar et al. · 2026 · PLoS neglected tropical diseases
57. Skin is a critical interface for Trypanosoma brucei transmission
    Parul Sharma, Mohammad El Kadri, Bruno Bucheton, Jean-Mathieu Bart, Annette MacLeod, Vincent Jamonneau, Mamadou Camara, Brice Rotureau · 2026 · Trends in Parasitology
58. Introduction to PBPK Modelling: Core Concepts for Small and Large Molecules
    Armin Sepp, Iain B. Gardner · 2026 · Handbook of experimental pharmacology
59. Pharmacokinetics, Immunogenicity, and Safety of a Modified YTE Antibody in Healthy Adults
    María del Rosario, J. N. J. M. De Hoon, Flonza Isa, Kenneth Turner, Jing Li, Joel Kantrowitz, Samit Ganguly, Sasha Fraser, Zhiyi He, Hong Yan et al. · 2026 · Clinical Pharmacology in Drug Development
60. MuSK agonistic antibody has therapeutic potential for MuSK antibody-positive myasthenia gravis
    K. Yamamoto, Akiyuki Uzawa, Genta Narazaki, Yoshikazu Nezu, Mami Yamazaki, Hirofumi Kondo, Kozo Yoneda, Masaya Shimada, Chigusa Yoshimura, Yoko Nakano et al. · 2026 · Neurotherapeutics
61. Proportionate evidence in biosimilar development: when a comparative efficacy study can still change the regulatory conclusion
    Sarfaraz K. Niazi · 2026 · npj Drug Discovery.
62. Monoclonal Antibodies Targeting Bacillus Calmette–Guérin (BCG) Outer Membrane Proteins Confer Protection Against Tuberculosis
    Huoming Li, Yanyan Jiang, Chenxi Shi, You Zuo, Hao Li · 2026 · Transboundary and Emerging Diseases